Indication
Eczema
Eczema is a broad term encompassing chronic, relapsing inflammatory dermatoses of the integumentary system, most commonly referring to atopic dermatitis. Read more about Eczema
0 drugs 0 manufacturers
Drugs that treat it
Common Eczema therapies.
No drugs are available
This indication does not currently contain public drugs.
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonEczema is a broad term encompassing chronic, relapsing inflammatory dermatoses of the integumentary system, most commonly referring to atopic dermatitis.
It affects populations across all ages, presenting most frequently in early childhood and often persisting into or manifesting in adulthood.
Pathophysiologically, the condition is driven by epidermal barrier disruption, heightened transepidermal water loss, immune dysregulation predominantly mediated by type 2 cytokine signaling, and cutaneous neurosensory hyperactivity.
Clinically, it is characterized by xerosis, intense pruritus, and localized erythematous macules or plaques that can progress to weeping, excoriation, and lichenification.
- medlineplus.gov
Eczema is a broad term encompassing chronic, relapsing inflammatory dermatoses of the integumentary system, most commonly referring to atopic dermatitis
- nih.gov
Eczema is a broad term encompassing chronic, relapsing inflammatory dermatoses of the integumentary system, most commonly referring to atopic dermatitis It affects populations across all ages, presenting most frequently in early childhood and often persisting into or manifesting in adulthood Clinically, it is characterized by xerosis, intense pruritus, and localized erythematous macules or plaques that can progress to weeping, excoriation, and lichenification
- nih.gov
Eczema is a broad term encompassing chronic, relapsing inflammatory dermatoses of the integumentary system, most commonly referring to atopic dermatitis It affects populations across all ages, presenting most frequently in early childhood and often persisting into or manifesting in adulthood Clinically, it is characterized by xerosis, intense pruritus, and localized erythematous macules or plaques that can progress to weeping, excoriation, and lichenification
- nih.gov
Pathophysiologically, the condition is driven by epidermal barrier disruption, heightened transepidermal water loss, immune dysregulation predominantly mediated by type 2 cytokine signaling, and cutaneous neurosensory hyperactivity
- nih.gov
Pathophysiologically, the condition is driven by epidermal barrier disruption, heightened transepidermal water loss, immune dysregulation predominantly mediated by type 2 cytokine signaling, and cutaneous neurosensory hyperactivity
- serenitybyadrsareen.com
Clinically, it is characterized by xerosis, intense pruritus, and localized erythematous macules or plaques that can progress to weeping, excoriation, and lichenification
Personalize your experience
Follow Eczema and get updates as they land.
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.